DARS2 Protein

Overview

flowchart TD
    DARS2["DARS2"] -->|"activates"| Tumor["Tumor"]
    DARS2["DARS2"] -->|"activates"| Carcinoma["Carcinoma"]
    DARS2["DARS2"] -->|"activates"| MYC["MYC"]
    DARS2["DARS2"] -->|"regulates"| cancer["cancer"]
    DARS2["DARS2"] -->|"regulates"| PINK1["PINK1"]
    DARS2["DARS2"] -->|"activates"| PINK1["PINK1"]
    DARS2["DARS2"] -->|"activates"| Metastasis["Metastasis"]
    DARS2["DARS2"] -->|"activates"| Invasion["Invasion"]
    DARS2["DARS2"] -->|"participates in"| senescence["senescence"]
    CDK4["CDK4"] -->|"activates"| DARS2["DARS2"]
    ERK["ERK"] -->|"activates"| DARS2["DARS2"]
    style DARS2 fill:#4fc3f7,stroke:#333,color:#000

DARS2 (Aspartyl-tRNA Synthetase 2, Mitochondrial) is a critical mitochondrial aminoacyl-tRNA synthetase that plays an essential role in mitochondrial protein synthesis. This enzyme is responsible for the ATP-dependent attachment of aspartic acid to its cognate mitochondrial tRNA (tRNA^Asp), which is fundamental for the translation of all 13 mitochondrial-encoded proteins 1. DARS2 is encoded by the DARS2 gene located on chromosome 12q24.1 and is ubiquitously expressed with highest levels in tissues with high mitochondrial demand, including the brain, heart, and skeletal muscle 2. ^{1Mitochondrial dysfunction in AD (2018)2018 · PMID 28715993Open reference}

The mitochondrial genetic system is distinct from the cytosolic translation machinery, requiring specialized components including mitochondrial aminoacyl-tRNA synthetases (mtaaRSs). DARS2 belongs to this unique family of enzymes that have evolved to function within the mitochondrial matrix and accurately translate the mitochondrial genome 3. ^{2DARS2 and mitochondrial quality control (2014)2014 · PMID 26000515Open reference}

Structure and Molecular Mechanism

DARS2 belongs to the class II aminoacyl-tRNA synthetase family and possesses the characteristic catalytic domain found in these enzymes. Unlike their cytosolic counterparts, mitochondrial aminoacyl-tRNA synthetases have evolved unique features to function within the mitochondrial environment and recognize mitochondrial tRNAs 4.

Protein Domains

The protein contains several functional domains:

1. N-terminal mitochondrial targeting sequence (MTS) - A 30-50 amino acid amphipathic helix that directs import into mitochondria via the TOM/TIM translocase machinery

2. Catalytic domain - The core ~400 amino acid region containing the active site for aminoacylation, with characteristic motifs including:

   • Motif 1: ATP binding

   • Motif 2: Amino acid binding

   • Motif 3: tRNA 3’-end binding

3. Anticodon-binding domain - Recognizes the specific anticodon sequence (GTC) of mitochondrial tRNA^Asp

4. Dimerization domain - Facilitates formation of functional homodimers, which is essential for activity

Catalytic Mechanism

The aminoacylation reaction proceeds through a well-characterized two-step mechanism:

Step 1: Aminoacyl-adenylate formation

Aspartic acid + ATP → Asp-AMP + PPi

Step 2: tRNA Charging

Asp-AMP + tRNA^Asp → Asp-tRNA^Asp + AMP

This reaction is essential for mitochondrial translation, as the mitochondrial genetic system requires properly charged tRNAs for accurate protein synthesis. The reaction is driven forward by pyrophosphate hydrolysis 5.

Role in Mitochondrial Function and Oxidative Phosphorylation

Mitochondria are essential for cellular energy production through oxidative phosphorylation (OXPHOS). The mitochondrial genome encodes 13 subunits of the electron transport chain complexes, along with 22 tRNAs and 2 rRNAs required for their translation 6. DARS2-mediated mitochondrial translation is therefore crucial for:

• Complex I (NADH:ubiquinone oxidoreductase) - 7 mitochondrial-encoded subunits (MT-ND1-6, MT-ND4L)

• Complex III (Cytochrome bc1 complex) - 1 mitochondrial-encoded subunit (MT-CYB)

• Complex IV (Cytochrome c oxidase) - 3 mitochondrial-encoded subunits (MT-CO1-3)

• Complex V (ATP synthase) - 2 mitochondrial-encoded subunits (MT-ATP6, MT-ATP8)

Proper assembly of these complexes requires accurate mitochondrial translation, making DARS2 essential for maintaining cellular energy homeostasis. Each OXPHOS complex requires precise coordination between mitochondrial and nuclear-encoded proteins, with mitochondrial translation serving as a critical bottleneck 7.

Clinical Implications and Disease Associations

Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)

Biallelic mutations in DARS2 cause a recessive disorder characterized by childhood-onset progressive leukoencephalopathy. This devastating neurological condition was first described in 2007 and is characterized by 8:

• Cerebellar ataxia - Progressive loss of coordination

• Spasticity - Muscle stiffness and rigidity

• Intellectual disability - Cognitive decline

• Brainstem dysfunction - Cranial nerve involvement

• Elevated cerebrospinal fluid lactate - Metabolic dysfunction

• White matter abnormalities - MRI findings

The most common mutation is a splice-site mutation (c.454-3C>G) that reduces DARS2 activity to ~20-30% of normal. Genotype-phenotype correlations show that residual enzyme activity correlates with disease severity 9.

Amyotrophic Lateral Sclerosis (ALS)

Recent studies have identified DARS2 mutations as a risk factor for ALS, particularly in sporadic cases. The mechanism involves multiple pathways 10:

1. Impaired mitochondrial function in motor neurons - Reduced OXPHOS capacity

2. Increased oxidative stress - ROS accumulation

3. Disrupted calcium homeostasis - ER-mitochondrial coupling

4. Altered energy metabolism - ATP depletion

5. Accelerated disease progression - Rapid motor neuron loss

Alzheimer’s Disease

While not directly causative, DARS2 dysfunction may contribute to Alzheimer’s disease pathogenesis through multiple mechanisms 11:

• Mitochondrial bioenergetic deficits - Reduced ATP production

• Impaired amyloid-beta metabolism - Altered APP processing

• Synaptic energy failure - Calcium dysregulation

• Increased neuronal vulnerability - Reduced resilience to stress

• Accelerated aging - Metabolic decline

Parkinson’s Disease

In PD, DARS2 may play a protective role:

• Mitochondrial complex I deficiency in dopaminergic neurons

• PINK1/PARKIN mitophagy pathway interactions

• Alpha-synuclein toxicity modulation

• LRRK2 pathway crosstalk 12

Therapeutic Implications and Drug Development

Targeting DARS2 and mitochondrial translation represents a promising therapeutic approach for neurodegenerative diseases:

Small Molecule Enhancers

Compounds that improve mitochondrial translation efficiency:

• Elamipretide (SS-31) - Mitochondrial-targeted peptide

• CoQ10 analogs - Electron transport chain support

• Riboflavin - Mitochondrial cofactor precursor

Gene Therapy Approaches

AAV-mediated delivery of functional DARS2:

• Tissue-specific promoters

• Self-complementary vectors

• miRNA silencing of mutant alleles

Mitochondrial Protectants

Agents that preserve mitochondrial function:

• Metformin - AMPK activation

• Nicotinamide riboside - NAD+ precursor

• PQQ - Mitochondrial biogenesis

Metabolic Modulators

Compounds that enhance alternative energy pathways:

• Ketogenic diet considerations

• Glutamine metabolism targeting

• Anaplerotic agents

Protein-Protein Interactions Network

DARS2 interacts with several proteins involved in mitochondrial function:

Research Directions and Future Perspectives

Current research areas include:

1. Understanding genotype-phenotype correlations - Predicting disease severity

2. Developing therapies for LBSL - Enzyme replacement considerations

3. Exploring DARS2’s role in age-related neurodegeneration - Sporadic disease

4. Investigating mitochondrial translation as a drug target - Broader applications

5. Understanding tissue-specific vulnerability - Why brain is affected

6. Biomarker development - Disease progression tracking

See Also

• Mitochondrial Diseases

• Leukodystrophy

• ALS Gene Therapy

• Mitochondrial Dynamics

• Oxidative Stress in Neurodegeneration

• Mitochondrial Protein Synthesis

• OXPHOS Complexes

• Motor Neuron Disease